Diagnosis and Management of Myositis-Associated Lung Disease.
antisynthetase syndrome
idiopathic pneumonia with autoimmune features
interstitial lung disease
myopathy
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
17
11
2022
revised:
04
01
2023
accepted:
23
01
2023
medline:
12
6
2023
pubmed:
11
2
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
Although interstitial lung disease (ILD) is a leading cause of morbidity and mortality in patients with inflammatory myopathies, the current definition and diagnostic criteria of autoimmune myositis remain inadequate to capture the large proportion of patients with lung-dominant disease. As a result, these patients present unique diagnostic and treatment challenges for even the most experienced clinicians. This article highlights the emerging role of autoantibodies in the diagnosis, classification, and management of patients with ILD. We propose alternative nomenclature to facilitate research on this unique patient population. Additionally, evidence supporting the various therapies used in the treatment of myositis-associated ILD is reviewed. The classification and treatment of patients with myositis-associated ILD remains challenging. A standardized therapeutic approach to these patients is lacking, and prospective studies in the field are needed to determine optimal treatment regimens.
Identifiants
pubmed: 36764512
pii: S0012-3692(23)00162-9
doi: 10.1016/j.chest.2023.01.031
pii:
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1476-1491Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.